Nonadherence to treatment protocol in published randomised controlled trials: a review by Dodd, Susanna et al.
TRIALS
Dodd et al. Trials 2012, 13:84
http://www.trialsjournal.com/content/13/1/84REVIEW Open AccessNonadherence to treatment protocol in published
randomised controlled trials: a review
Susanna Dodd1*, Ian R White2 and Paula Williamson1Abstract
This review aimed to ascertain the extent to which nonadherence to treatment protocol is reported and addressed
in a cohort of published analyses of randomised controlled trials (RCTs). One hundred publications of RCTs,
randomly selected from those published in BMJ, New England Journal of Medicine, the Journal of the American
Medical Association and The Lancet during 2008, were reviewed to determine the extent and nature of reported
nonadherence to treatment protocol, and whether statistical methods were used to examine the effect of such
nonadherence on both benefit and harms analyses. We also assessed the quality of trial reporting of treatment
protocol nonadherence and the quality of reporting of the statistical analysis methods used to investigate such
nonadherence. Nonadherence to treatment protocol was reported in 98 of the 100 trials, but reporting on such
nonadherence was often vague or incomplete. Forty-two publications did not state how many participants started
their randomised treatment. Reporting of treatment initiation and completeness was judged to be inadequate in
64% of trials with short-term interventions and 89% of trials with long-term interventions. More than half (51) of the
98 trials with treatment protocol nonadherence implemented some statistical method to address this issue, most
commonly based on per protocol analysis (46) but often labelled as intention to treat (ITT) or modified ITT (23
analyses in 22 trials). The composition of analysis sets for their benefit outcomes were not explained in 57% of trials,
and 62% of trials that presented harms analyses did not define harms analysis populations. The majority of defined
harms analysis populations (18 out of 26 trials, 69%) were based on actual treatment received, while the majority of
trials with undefined harms analysis populations (31 out of 43 trials, 72%) appeared to analyse harms using the ITT
approach. Adherence to randomised intervention is poorly considered in the reporting and analysis of published
RCTs. The majority of trials are subject to various forms of nonadherence to treatment protocol, and though trialists
deal with this nonadherence using a variety of statistical methods and analysis populations, they rarely consider the
potential for bias introduced. There is a need for increased awareness of more appropriate causal methods to
adjust for departures from treatment protocol, as well as guidance on the appropriate analysis population to use for
harms outcomes in the presence of such nonadherence.
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Adherence to prescribed medication
Adherence to long-term therapy has been defined as ‘the
extent to which a person’s behaviour - taking medication,
following a diet, and/or executing lifestyle changes, corre-
sponds with agreed recommendations from a health care
provider’ [1]. Nonadherence to prescribed treatment can
take a variety of forms, ranging from not starting treatment* Correspondence: s.r.dodd@liv.ac.uk
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reproduction in any medium, provided the orat all, to taking treatment at the incorrect time or dose,
‘drug holidays’ (stopping treatment for a period of time be-
fore restarting), ‘white-coat compliance’ (improved adhe-
rence to treatment regimen around the time of
appointment with clinician) and permanent discontinuation
of treatment [2]. Nonadherence is a problem affecting
many therapeutic areas [3], and has been cited as the pri-
mary reason for suboptimal clinical benefit, causing compli-
cations of disease, reduced quality of life and wasted health
care resources [1]. A vast amount of research has explored
its causes [4], and numerous factors related to the patient,
disease, treatment, health care provider and health caretd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Despite this, there has been little improvement in adhe-
rence rates, with an estimated 1/3 to 1/2 of patients consis-
tently failing to comply in some way with prescribed
medications [4], and adherence to lifestyle prescriptions is
even lower [3].
Nonadherence in randomised controlled trials
In a clinical trial setting, treatment adherence implies
following the treatment regimen specified in the trial proto-
col, and is thus dependent not only on the action of the
trial participant but also on the cooperation of the treat-
ment provider. Treatment providers may deviate from the
randomised treatment protocol when administering or pre-
scribing treatment, by changing the type, dose or schedule
of drug prescribed or failing to deliver treatment according
to the procedure specified in the protocol (for example,
during a surgical operation). Alternatively, the treating cli-
nician may decide over the course of the trial treatment
period that it would be in the best interest of the patient to
deviate more substantially from the treatment protocol and
to instead deliver an entirely different treatment.
Trial participants may also face greater barriers to ad-
herence than those being treated in a usual care setting.
Although it is possible that those who agree to take part
in a trial may naturally be more motivated to adhere to
their prescribed treatment than those in the general
population, the trial treatment protocol may be rather
more involved or demanding, and may be accompanied
by more intense follow-up or invasive assessments than
would be experienced in general practice, all of which
can hinder participation. Also the uncertainty about the
efficacy of a drug being tested in the trial setting may
mean that trial participants are less likely to persevere
with unpleasant side effects of treatment than those who
have been assured of the efficacy of their treatment.
Trial participant nonadherence may take the form of
premature participant withdrawal from the study (com-
monly referred to as withdrawal of consent or partici-
pant discontinuation of the study) or discontinuation of
treatment, either permanently (often referred to as with-
drawal from treatment) or temporarily (treatment inter-
ruptions). Other forms of nonadherence include failing
to follow treatment protocol as regards timing or dosage
of randomised treatment, or failing to initiate allocated
treatment at all. Thus, compared with a regular clinical
setting, an added dimension to the problem of non-
adherence arises in clinical trials because of the required
adherence of both trial participants and treatment provi-
ders to the potentially stringent trial protocol.
Reporting of adherence information
Clinical trials often fail to report important features of
design and analysis that are necessary to ascertain themethodological quality of the trial [5-11]. Lack of adequate
trial reporting led to the development (and two further
updates) of the Consolidated Standards of Reporting Trials
(CONSORT) statement [12-14], which aimed to improve
reporting of trial methodology and results by providing
authors with a checklist of items recommended for inclu-
sion in trial publications. CONSORT recommends repor-
ting ‘for each group the numbers of participants who were
randomly assigned, received intended treatment and were
analysed for the primary outcome. . .Knowing the number
of participants who did not receive the intervention as allo-
cated or did not complete treatment permits the reader to
assess to what extent the estimated efficacy of therapy
might be underestimated in comparison with ideal circum-
stances.’ Use of CONSORT flow diagrams to illustrate pa-
tient flow through the trial has become increasingly
common [15], but the information presented in the flow
diagram may not be detailed enough to ascertain the true
extent and nature of any nonadherence to treatment proto-
col that may have occurred in a trial.
Statistical analysis of nonadherence data
When a trial is subject to nonadherence to treatment
protocol, the appropriate statistical method of analysis
will be depend on the research question of interest. The
standard method of analysis by intention to treatment
(ITT) classifies participants according to the treatment
to which they were originally randomised and ignores
information on actual treatment received [16]. ITT is
thus useful as an assessment of the trial policy of assign-
ing participants to therapy (also called use-effectiveness
or simply the effectiveness of treatment) and should be
presented as a primary analysis for all trials, as it reflects
the original trial design.
When offered a new treatment, a different question
that is likely to be of particular interest to the patient is
‘What treatment effect can I expect if I adhere to treat-
ment?’ This causal effect of treatment may also be of
interest to clinicians, health care regulators and pharma-
cologists [17]. In the presence of treatment protocol
nonadherence, however, an ITT does not provide an es-
timate of the actually administered treatment (also called
method-effectiveness or efficacy of treatment [18]) or
the causal effect of treatment [19], as the inclusion of
nonadherent participants in ITT analysis generally
diminishes the estimated treatment effect [16]. Thus, de-
pending on the research question, an ITT approach may
need to be supplemented by additional analyses which
account for deviations from protocol [17]. In particular,
the analysis of harms outcomes using an ITT approach
is not recommended because, as in equivalence or non-
inferiority trials [16], diminishing the estimate treatment
effect in a harms analysis is anti-conservative, making a
harmful treatment more likely to be accepted as
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ITT approach to the analysis of safety simply adds to the
risk of failing to identify potential safety problems, and
is therefore never advocated’.
Commonly used methods of analysis to address the
issue of nonadherence to treatment protocol and thus
provide an estimate of treatment efficacy include per
protocol (PP) and as treated (AT) analyses. PP analysis
typically excludes or censors participants who deviate
from treatment protocol, but exclusion of participants
from the analysis in this way can lead to selection bias,
as the treatment protocols being compared are likely to
present different challenges to adherence and the resul-
tant residual subgroups may not be comparable [21].
Similarly, AT analysis of patients introduces selection
bias by simply analysing participants according to treat-
ment received without regard to their randomised
allocation.
There exist other statistical techniques to estimate causal
effects of treatment and thus account for nonadherence to
treatment protocol without introducing biases inherent to
PP or ATanalyses, such as randomisation-based efficacy es-
timation methods, which estimate efficacy while taking into
account departures from randomised treatment and yet
maintaining the balance produced by randomisation [17].
Such analysis techniques are not commonly used, as they
tend to be more complex and computationally intensive
than the more naive but inherently biased techniques of
analyses such as PP and AT, and they necessarily rely on
potentially unverifiable assumptions. However, this area of
research is growing, and interested readers are directed to-
wards introductory texts such as Bellamy et al. [22], Little
and Rubin [23] or Greenland et al. [24].
Aims
This review aimed to ascertain the extent and nature of
nonadherence to randomised treatment reported in pub-
lished trials, how such nonadherence is handled in sta-
tistical analyses of benefit and harms outcomes, and
how well such nonadherence, and the statistical methods
to deal with it, are reported in published randomised
controlled trials (RCTs).
Methods
Terminology
In this article, the term ‘nonadherence to randomised
treatment’ is used to indicate any deviation on the part
of the patient or treatment provider to the trial treat-
ment protocol, or any treatment change agreed with
medical staff but not permitted by the trial protocol.
Protocol-permitted treatment changes can also present
problems of interpretation but these were not consi-
dered in this review. For example, discontinuation of the
randomised treatment for safety reasons as specified inthe protocol, or premature stopping of a trial according
to a predefined stopping rule, were not considered as
examples of deviations from treatment protocol in this
review.
For the purposes of assessing the adequacy of trial re-
porting, we have extended the definitions given by Vrijens
et al. [25] for the three quantifiable phases of patient adhe-
rence to prescribed medication (initiation, discontinuation
and implementation) for use in a clinical trial setting, where
the intervention may be nonpharmacological and where
adherence to treatment protocol can be influenced by treat-
ment providers when administering or prescribing treat-
ment as well as by participants, because of the required
adherence to the trial treatment protocol.
Thus adherence is defined as the degree of corres-
pondence between a participants’ intended randomised
treatment prescription and their actual history of treat-
ment received over the course of the protocol-specified
treatment period. Adherence is split into the following
phases: initiation of randomised treatment occurs when
the participant begins their randomised intervention;
discontinuation is defined as the permanent cessation of
randomised intervention; the implementation period is
the time between these two events. Persistence is defined
as perseverance with the randomised treatment as per
the trial protocol until the end of the protocol-defined
treatment period.
Given that the adequacy of trial reporting on adherence
to treatment protocol depends on the duration and com-
plexity of trial-specific interventions, we classified trials
according to whether the trial interventions were given at a
single or multiple time points. Trials with treatment given
at multiple time points (referred to as longitudinal treat-
ment periods) were divided into ‘short-term intervention
trials’ involving treatment given at a few discrete time
points (for example, single daily dose over the course of a
week) or continuously over a short period of time (for
example, infusion given for one hour), and ‘long-term inter-
vention trials’.
Key points to be reported
In order to judge the quality of trial reporting, and the
statistical handling of treatment protocol nonadherence,
it is important to identify key points that should be ex-
plicitly reported in each publication. Table 1 documents
the recommendations for explicit reporting of informa-
tion relating to adherence to treatment protocol, with
quoted justification taken from the CONSORT 2010
elaboration document [13] unless stated otherwise. All
trials should report the number of randomised partici-
pants and the number of participants who initiated their
randomised intervention. Longitudinal treatment period
trials were also expected to have reported on treatment
persistence: in the interest of a conservative assessment
Table 1 Recommendations for explicit reporting of information relating to adherence to treatment protocol
Report for all trials Report according to treatment duration Report reasons for justification
Single (one-off)
intervention
Short-term
intervention
Long-term
intervention
1. Randomisation Randomiseda ‘Crucial count for defining trial size and
assessing whether a trial has been
analysed by intention to treat’; necessary
to determine whether all trial participants
received treatment and were included in
analysis.
2. Adherence to treatment protocol
a. Initiation Initiated (or received)
randomised
interventiona
Initiated randomised
interventiona
Initiated randomised
interventiona
Those not initiating
randomised intervention
‘Knowing the number of participants who
did not receive the intervention as
allocated or did not complete treatment
permits the reader to assess to what
extent the estimated efficacy of therapy
might be underestimated in comparison
with ideal circumstances.’
b. Completion/persistenceb Completed
randomised
interventiona
Persisted with
randomised intervention
as required by treatment
protocola
Those who did not
complete/persist with
randomised intervention
c. Adherence over treatment periodc
i) Method Description of method used to measure
adherence over treatment period (and of an
additional method to check reliability if trial
involves participant-administered intervention)
If participant compliance data are
collected, the reliability of the method
used to record compliance should ideally
be checked by use of another method (for
example, treatment diaries backed up by
counts of remaining tablets at the end of
each course of treatment) [26]
ii) Justification for definition Justification for any reported definition of
adherence (for example, if a threshold is used to
define adequate adherence)d
‘If patients are to be divided into
“compliant” and “noncompliant” groups,
the division should ideally be made on the
grounds of the relationship of the
compliance level to the therapeutic
response or outcome’ [29]
iii) Results Measure of participant and/or treatment
provider adherence with randomised
intervention (as appropriate)d
Any participant or
treatment provider
nonadherenced
3. Analysis
a. Analysed Analyseda Any exclusion of
participants from analysis
‘Attrition as a result of loss to follow up,
which is often unavoidable, needs to be
distinguished from investigator-
determined exclusion for such reasons as
ineligibility, withdrawal from treatment,
and poor adherence to the trial
protocol. . .Participants who were excluded
after allocation are unlikely to be
representative of all participants in the
study.’
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Table 1 Recommendations for explicit reporting of information relating to adherence to treatment protocol (Continued)
b. Analysis set composition How analysis sets
differ from
randomised groups
Any difference between
analysis sets and
randomisation groups
‘Erroneous conclusions can be reached if
participants are excluded from analysis,
and imbalances in such omissions
between groups may be especially
indicative of bias.’
Quoted justification is taken from CONSORT 2010 elaboration document [13] unless stated otherwise. aReport numbers of participants in each randomised intervention group satisfying condition listed in each cell.
bPersistence is defined as perseverance with prescribed treatment until the end of the treatment period. cAdherence is defined as a measure of the degree of correspondence between prescribed treatment and actual
treatment received by participant. dNote that, depending on the complexity of treatment, it may not be necessary for trials with a short-term intervention to report on adherence over the treatment period.
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were required only to have reported on the number of
patients who completed intervention (or the number
who discontinued randomised intervention prema-
turely). Long-term interventions are, however, more
likely to result in treatment interruptions or deviations,
so patients who were still taking treatment at the end of
the protocol-determined treatment period may not have
been fully adherent to the treatment schedule for the
whole duration of treatment. Thus publications of trials
with long-term interventions were judged according to
whether they had supplemented their reporting of the
number of participants who persisted with the interven-
tion according to the treatment protocol (or conversely
the number of participants who prematurely discon-
tinued randomised intervention) with some measure of
participant and/or treatment provider adherence to
treatment protocol (as appropriate, depending on
whether administration of treatment was by the partici-
pant or the treatment provider) over the implementation
period. Methods used to assess participant or health care
provider adherence to the treatment protocol should be
described, and clinical justification given for any defin-
ition used to define adherence. In particular, clinical
trials involving a participant-administered intervention
are recommended to use a reliable measure, and ideally
a combination of measures, to accurately record partici-
pants’ adherence data [26]; thus, in this review, publica-
tions of such trials with a long-term intervention period
were judged according to whether they collected and
reported details of the methods used to assess, and
check reliability of, participant adherence. We also
recorded whether the use of any adherence threshold to
split participants into ‘good’ and ‘poor’ compliers was
explained. Although such dichotomisation is not reco-
mmended [27], any threshold should be specified in the
protocol; otherwise, there may be suspicion that an opti-
mal adherence cut-off has been selected on the basis of
the results to allow the most favourable adherence rates
to be reported, as the ‘definition of non-compliance is
malleable and could be inadvertently manipulated for
benefit of investigators’ [28].
Analysis sets for both benefits and harms outcomes
should be defined explicitly, with reasons given for the
exclusion of any patients from the analysis. If there is
any difference between the defined analysis sets and the
intervention groups as randomised, this should be stated
clearly and any potential resultant bias should be
discussed.
Selection of reports
A search of MEDLINE (using terms randomi$ed con-
trolled trial$ or controlled trial$ or controlled clinical
trial$ or RCT$) was carried out in order to identify trialreports published in BMJ, the Journal of the American
Medical Association (JAMA), The Lancet and New
England Journal of Medicine (NEJM) during 2008. Of
the 698 articles obtained from the initial search, 281 (49
from BMJ, 53 from JAMA, 84 from The Lancet and 95
from NEJM) remained after the deletion of duplicates,
comments, systematic reviews and meta-analyses. A
sample of 100 trial reports were randomly selected from
these articles, 16 of which were from BMJ, 20 from
JAMA, and 32 each from The Lancet and NEJM.
Secondary publications
Five of the selected studies were secondary publications
of recent trials (original publications were in NEJM
[30,31], JAMA [32], American Journal of Medicine [33]
and Neurology [34]). In these cases, for the purposes of
reporting adherence data, both the primary and second-
ary publications of the same trial were considered to be
the unit of analysis.
Data extraction
SD recorded the trial publication characteristics relating
to the quantitative items listed in Table 1 using a piloted,
standardised form. In cases of any doubt or ambiguity,
the paper was reviewed by PW.
Results
Quality of reporting on departures from treatment
protocol
The vast majority of trial reports (96%) included a
CONSORT flow diagram. Table 2 summarises the qua-
lity and completeness of reporting on randomisation,
adherence to treatment protocol and analysis in the
CONSORT flow diagrams and the text. All 100 trials
stated the numbers randomised, but only 58 publica-
tions stated how many patients actually initiated their
allocated treatment. All trials provided some informa-
tion on the number of participants included in analysis
of the primary outcome, but this information was not
always provided for secondary outcomes, particularly
when a large number of outcomes was analysed. Forty-
three trial reports included an explicit explanation of
the composition of the analysis sets used for benefit
outcomes, 48 trials labelled the analysis sets (47 ITT
and one PP) without further explanation of how the
analysis sets were composed, and no details on the
composition of benefit outcome analysis sets were
given in the remaining nine trials.
Table 3 provides a breakdown of persistence and ad-
herence information reported in the 88 studies with lon-
gitudinal treatment periods. The majority (81, 92%)
provided some information on treatment completeness,
but this was sometimes incomplete or vague.
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pleteness was judged to be adequate in only 7 (11%) of
66 trials with long-term interventions (requiring report-
ing of treatment initiation, persistence and some meas-
ure of adherence over the implementation period) and 8
(36%) of 22 trials with short-term interventions (requir-
ing reporting of treatment initiation and completion).
Reporting of treatment receipt was judged to be suffi-
cient in 10 (83%) of 12 trials with a one-off treatment.
Thirty-three trials with the intervention given at mul-
tiple time points reported information on treatment
interruptions (two trials) or a measure of average adher-
ence over the treatment period, on the part of the par-
ticipant (28 trials) and/or treatment provider (four trials;
one trial reported on adherence of both the participant
and treatment provider), but six of these reported this
information for the whole trial or combinations of inter-
vention groups rather than by individual intervention
group. Reported measures included the percentage of
patients who achieved a particular arbitrary level of ad-
herence in terms of the proportion of doses received or
the proportion of time patients were supplied with ran-
domised drug over the course of the trial.
Less than half (21, 47%) of the 45 trials with
participant-administered treatment mentioned checking
adherence, and only five of these assessed the reliability
of the adherence data using a second method. The most
common methods to ascertain participant adherence
involved counting pills (11 trials) or questioning the par-
ticipant in some manner (10 trials), even though these
methods are not considered to be particularly reliableTable 2 Reporting of key points in 100 trial reports
Report for all trials
Sin
i
1. Randomisation 100 (100%)
2. Adherence to treatment protocol
a. Initiation -
b. Completion/persistence -
c. Adherence over implementation period
i) Method -
ii) Justification for definition -
iii) Results -
3. Analysis
a. Number analysed 100 (100%)e
b. Analysis set composition 43 (43%) [91 (91%)]f
Cells left blank are not required. aNumber (%) of trials that fully reported [partially r
short-term (n = 2) or long-term (n = 45) intervention trials with patient-administered
long-term (n = 18) intervention trials with patient-administered treatment that repo
that fully reported [partially reported] some measure of nonadherence on the part
number included in analysis of primary outcome. fNumber (%) of trials that fully rep
stated that analysis was by intention to treat (n = 47) or per protocol (n = 1) but did[26]. More accurate methods, such as medication events
monitoring systems or measurement of drug metabolite
or marker in bodily fluids, were not used, except in one
trial that used blood tests. Nineteen trials (17 of which
were drug trials) explicitly defined adherence in terms of
the proportion of intervention received (or proportion of
time supplied with drug) or discontinuation of interven-
tion. Thirteen of these specified a threshold to define ad-
equate adherence (ranging from 50% to 100% but most
commonly 80% (four trials) or two-thirds (three trials))
but no report included an explanation for the choice of
thresholds.
Twelve (34%) of the 35 trials of nonpharmacological
interventions mentioned that adherence of treatment
providers was monitored, four of which reported quanti-
tative results.
Ambiguities in trial reports
Commonly used terms in CONSORT flow diagrams al-
luding to nonadherence (or adherence) to treatment
protocol such as ‘discontinued’, ‘completed study proto-
col’, ‘withdrew’, ‘protocol deviations’ and ‘loss to follow-
up’ do not provide explicit information on completeness
of treatment unless accompanied by clarification on tim-
ing or treatment actually received. For example, the term
withdrew can indicate withdrawal from treatment only,
withdrawal from further follow-up or withdrawal of con-
sent regarding inclusion of a patient’s data in the study.
In 13 (62%) of the 21 trials that included the term with-
drew in the flow diagram, it was not possible to ascertain
whether the participants who withdrew had actuallyReport according to treatment duration
gle (one-off)
ntervention
(n= 12)
Short-term
intervention
(n= 22)
Long-term
intervention
(n = 66)
- - -
10 (83%) 15 (68%) 33 (50%)
- 12 (55%) [17 (77%)]a 31 (47%) [51 (77%)]a
- 1 (50%)b 21 (47%)b
- 0 (0%)c 0 (0%)c
- 5 (23%)d 22 (33%) [28 (42%)]d
- - -
- - -
eported] on persistence or completion of randomised treatment. bNumber of
treatment (2) is used as denominator for %. cNumber of short-term (n= 1) or
rted adherence definition is used as denominator for %. dNumber (%) of trials
of patient or treatment provider. eNumber (%) of trials that reported the
orted [partially reported] analysis set composition; partially reporting trials
not explicitly explain composition of analysis sets.
Table 3 Breakdown of persistence and adherence reporting in 88 trials with longitudinal intervention periods
Short-term intervention
(n = 22)
Long-term intervention
(n= 66)
Total
Persistence
Fully reporteda 12 31 43
Partially reported
onlyb
5 20 25
Partially reported, including reporting the number of participants who:
Withdrew 1 3 4
Withdrew consent 1 2 3
Lost to follow-up (during treatment) - 3 3
Lost to follow-up (unclear whether during treatment) 1 1 2
Discontinued due to certain event(s)c - 6 6
Completed study 3 8 11
Discontinued study - 2 2
Completed different aspects of treatment protocol (reported separately)d - 2 2
Completed treatment in trial overall (not by treatment group) 1 1 2
Not reported 5 15 20
Adherence over implementation period
Fully or partially reported, including reportingb 5 22 (6) 27
(6)
Average measure of participant adherencee 2 20 (6) 22
(6)
Average measure of adherence on part of treatment provider 3 1 4
Treatment interruptions - 2 2
Not reported 17 38 55
Overall
reporting
Some reporting 19 62 81
Persistence reported only (fully or partially) 14 34 48
Adherence reported only (fully or partially) 2 11 13
Both persistence and adherence reported (fully or partially) 3 17 20
Not reported 3 4 7
aReported the number of participants still taking treatment at end of treatment period, or the number who completed treatment, or who discontinued or
withdrew from randomised intervention prematurely. bTrial publications may have reported on one more than one of the categories listed. cReported numbers
discontinuing only for one reason (for example, adverse events). dUnable to discern how many participants received entire intervention. eFigure in brackets
indicates number of publications reporting adherence measure for overall trial or combinations of intervention groups, not by individual intervention group.
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timing of withdrawal was not clear in 8 (38%) of the 21
trials that described participants who ‘withdrew consent’
in the flow diagram.
Fifteen (18%) of the 85 trials with a longitudinal treat-
ment which presented a flow diagram referred to the
number of participants who ‘received’ when they meant
‘initiated’ treatment; this could potentially mislead read-
ers as use of the word received may be incorrectly inter-
preted as receipt of the entire intervention.
Three trials with a long-term intervention period re-
ferred in the CONSORT diagram (and four more re-
ferred in the text) to the number of patients who
‘completed’ treatment when it would have been moreaccurate to report this figure as the number ‘still on
treatment at end of treatment period/trial follow-up’, as
completion of treatment may imply complete adherence
to, as well as persistence with, randomised intervention
throughout the treatment period.
Extent and nature of nonadherence to treatment protocol
reported
Ninety-eight publications reported at least one form of
departure from treatment protocol (see Table 4). Direct
comparison of the extent of departure from treatment
protocol across trials is not straightforward, as trials dif-
fered greatly in terms of type and duration of interven-
tion, definitions used to define nonadherence and level
Dodd et al. Trials 2012, 13:84 Page 9 of 16
http://www.trialsjournal.com/content/13/1/84of reporting. However the distribution of percentage of
patients displaying some form of deviation from treat-
ment protocol (or the average degree of nonadherence
in a single trial), based on information reported in the
trial publications, can also be seen in Table 4.Handling of departure from treatment protocol in
statistical analyses
Benefit outcomes
Of the 98 trials that reported some form of nonadher-
ence to treatment protocol, 51 (52%) reported some
form of analysis method to handle such nonadherence
in the analysis of benefit outcomes (see Table 5). Forty-
six trials adjusted for treatment protocol deviations by
carrying out analysis based on PP analysis (total not
shown in Table 4), by censoring or excluding partici-
pants who had violated the treatment protocol in some
way, but half of these analyses were labelled as ITT or
modified ITT analyses. Only one trial [35] aimed to ad-
dress the bias introduced from potentially informative
censoring of patients at the point of deviation from
treatment protocol, by weighting their censoring by the
inverse of their estimated probability of adhering, as
advocated by Robins and Finkelstein [36]. Other analysis
methods that dealt with departures from randomised
treatment included treating discontinuation of treatment
(or starting disallowed or rescue medication) as a treat-
ment failure in analysis (three trials), AT analyses (ana-
lysing participants according to the actual treatment
received regardless of randomisation allocation) (three
trials) and analysing outcomes concerned with time to
discontinuation of trial drug (four trials).
Of the 20 trials where adjustment for nonadherence
was explicitly compared with other analyses, four trials
reported that adjustment for nonadherence resulted in
more extreme treatment effects; in the remaining 16
trials it was not reported to have made a substantial dif-
ference to conclusions.Harms outcomes
Of the 69 trials that presented a harms analysis, 43
(62%) did not define the specific population set that was
used in this analysis (see Table 6). Of the 26 trials that
specifically defined a harms analysis population, the ma-
jority (18, 69%) specified that analysis was based on ac-
tual treatment received and included all patients who
had received at least one administration of study agent,
but only one study specifically stated that participants
who received the alternative treatment rather than that
allocated to them would be included in the alternative
treatment group for this analysis. The remaining 43
trials that did not define a specific harms analysis popu-
lation most commonly appeared to analyse the harmsoutcomes according to the specified benefit analysis
population (31 ITT, 2 PP).
Discussion
Reporting of adherence information
We found that the vast majority of RCTs are subject to
at least one form of nonadherence to treatment protocol,
most commonly incomplete treatment or non-receipt of
allocated treatment, but even the most basic adherence
information on initiation, completion and premature
discontinuation of treatment was not presented in some
trials. Perhaps most remarkable was the fact that 42% of
the publications did not explicitly state how many
patients actually initiated their randomised treatment.
The template for the CONSORT flow diagram suggests
that, in the treatment allocation box, trialists should re-
port the number of participants who ‘received’ the allo-
cated intervention, and in the follow-up box, they
should then report the number who ‘discontinued’ the
intervention. However, except in the case of trials with
treatment given at a single time point (only 12% of the
trials in this review), it would be more accurate and less
misleading to ask trialists to report the number of parti-
cipants who ‘initiated’ rather than ‘received’ the inter-
vention, as ‘initiated’ is unambiguous but ‘received’ may
be interpreted either as initiation or as receipt of the en-
tire study treatment. Indeed, in the 2010 CONSORT
elaboration document, the table which details the infor-
mation required in the flow diagram (Table 3) states that
the treatment allocation box should include the number
of participants who ‘completed’ treatment as allocated,
rather than ‘initiated’ or at least ‘received’.
The absence of any explicit reporting of the number of
participants who initiated intervention may lead readers
to assume that all randomised participants at least
started their randomised intervention. Indeed Vrijens
et al. [25] state that, in the context of clinical trials of
prescribed medication, given that the first dose of a
randomised medication is usually administered on site
following informed consent, ‘it is often assumed that ini-
tiation is implicit for all included patients’. However,
more than one-third (26, 38%) of the 69 drug trials in
our review included participants who did not initiate
their randomised intervention.
Other inadequacies in reporting related to departures
from the treatment protocol were evident in this review.
For example, none of the 13 trial reports that specified a
cut-off to define adequate adherence included an explan-
ation for the choice of threshold. As discussed by Vrijens
and Urquhart [27], the use of ad hoc threshold values,
such as the ‘often-used but never pharmacometrically
justified’ adherence criterion of taking at least 80% of
prescribed doses to define the sufficient exposure to
drugs needed to achieve satisfactory therapeutic results, is
Table 4 Reported forms of departure from treatment protocol
Number (%)
Reported some form of nonadherence to treatment protocola 98
Participants who did not initiate allocated treatment 39
Participants with incomplete treatment (among those who initiated allocated treatment) 78
Participants who switched trial treatments 12
Participants who started open label treatment (not as per protocol) 7
Participants who started disallowed or non-trial treatment 4
Evidence of contamination between treatment groups 3
Other forms of nonadherence to treatment dose or schedule 23
Nonadherence on the part of treatment providers 12
Did not report any nonadherence to treatment protocol 2
Percentage of patients experiencing or displaying some form of nonadherence to treatment protocol
None reported 2
0 to 5% 23
5 to 10% 10
10 to 20% 22
20 to 30% 11
30 to 50% 12
>50% 9
>0% but unclearb 11
aTrial publications may have reported the number of participants in more than one of the categories listed. bFor example, trial report states only that the
treatment providers were not adherent to some degree, or it was not possible to distinguish withdrawal from treatment for legitimate reasons (for example, death
or treatment changes permitted by protocol following adverse events) from withdrawal due to nonadherence.
Dodd et al. Trials 2012, 13:84 Page 10 of 16
http://www.trialsjournal.com/content/13/1/84unacceptable, as such a threshold will depend on a wide
range of underlying drug-, disease- and formulation-
specific pharmacodynamics.
Statistical methods to deal with departures from
treatment protocol
Although more than half (51 out of 98, 52%) of the trials
that were subject to nonadherence to treatment protocol
implemented a statistical analysis method to deal with
such nonadherence when analysing benefit outcomes,
these were most commonly based on variations of PP
analysis (46 trials) and very few recognised, or sought to
address, the potential for bias introduced when exclud-
ing or censoring patients at the point of deviation from
the treatment protocol. One trial [35] sought to address
the potential bias caused by censoring of patients at the
point of deviation from the treatment protocol, using
the inverse probability of censoring weighted method
[36], and one other trial [37] provided justification for
the decision to exclude participants who had not
received the allocated intervention, citing Fergusson
et al. [38] and stating that the ‘omission [of such
patients] would be equally distributed between groups,
would be unrelated to treatment assignment, and would
not bias outcome ascertainment’. Trial publications com-
monly presented insufficient detail or explanation on theanalysis sets used for benefit and harms outcomes. The
composition of analysis sets for their benefit outcomes
were not explained in 57% of trials, and 62% of trials that
presented harms analyses did not specifically define harms
analysis populations. This common lack of discussion
regarding whether, and if so why, patients were excluded
from analysis and the potential biases which may result
from such exclusions indicates a low priority given to the
issue of nonadherence to treatment protocol in the ana-
lysis of published trials.
ITT analysis to handle nonadherence to the treatment
protocol
Seventeen trials carried out what were referred to as
ITT analyses but the ITT analysis set excluded partici-
pants if they did not adhere to the treatment protocol in
some manner. This mislabelling of ITT analyses has
been noted in previous reviews of ITT analyses in recent
trial publications [39-42]. Comparison of previous
reported results with those here suggests that the use of
the phrase ITT to describe analyses of RCTs is becoming
more common (48% in 1999 [41], 71% in 2007 [39] and
83% in 2008), at least in these four leading medical jour-
nals, but that the correct definition of ITT analysis is
being followed less commonly: 13% of ITT trials pub-
lished in 1999 excluded participants who did not receive
Table 5 Statistical methods addressing nonadherence to treatment protocol
Number
(%b)
Definition of analysis set Number
Reported a statistical method addressing nonadherence to
treatment protocola
51 (52)
Variant of PP
Primary PP analysis described as ‘PP’ 18
Included only those participants who received full
randomised intervention
8
Included only those participants who received at least one
dose of randomised intervention
2
Minimum degree of adherence required 5c
Included only those taking treatment at particular time
during trial
1
Excluded participants if they started disallowed medication 1
Censored participants at time of stopping treatment 1
Primary PP analysis described as ‘ITT’ or ‘modified ITT’ analysis 23
Included only those participants who received full
randomised intervention
1
Included only those participants who received at least one
dose of randomised intervention
16
Included only those participants who received the single
treatment
3
Excluded participants if they deviated from treatment
protocol
3
Sensitivity analysis 12
Included only those participants who received full
randomised intervention
4
Excluded participants if they received disallowed
treatments
2
Minimum degree of adherence required 2d
Censored participants at the point of deviation from
treatment protocol
4e
Inverse probability of censoring weighted method 1f
Subgroup analysis 2g
Unlabelled analysis 1h
As treated analysis 3
Discontinuation of treatment analysed as treatment failure 3
Time to treatment discontinuation included as trial outcome 4
Did not report a statistical method to address nonadherence to
treatment protocol
47 (48)
aNine trials carried out two methods of analysis, two trials carried out three methods and one trial carried out four methods. bNumber of trials reporting some
form of nonadherence (98) is used as denominator for %. cAdherence thresholds used were 60%, 2/3, 75%, 80% and 90%. dAdherence thresholds used were 2/3
and 5/6. eCensoring times: time of starting disallowed intervention, when participants reported taking less than 2/3 of their medication in the past year, when
received treatment out of trial, or censored following six-month lag after receiving less than 80% of drug. fCensored when received <80% of drug, weighted by
the inverse probability of each participant’s estimated adherence probability. gAnalysis split into two groups (according to whether participants had taken more or
less than 50% of the prescribed medication) in one trial and into three groups (according to the proportion (>90%, 75-90% or <75%) of their time at risk that
they were supplied with drug) in other trial. hIncluded if received at least one dose of treatment. ITT: intention to treat; PP: per protocol.
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such trials in our review (P= 0.086, Pearson’s χ1
2
statistic = 2.95).
One reason for the exclusion of participants who did not
receive treatment in ITTanalyses may be the fact that more
relaxed definitions of ITT have been advocated in the past.For example, Gillings and Koch [43] considered that, under
most circumstances, the ITT population can be defined as
all randomised patients who are known to have received at
least one dose of treatment and who provide follow-up data
for one or more of the key efficacy variables. Also the
International Conference on Harmonisation of Technical
Table 6 Harms analysis populations in 69 trials that presented harms analyses
Number (%a)
Harms analysis population specifically defined
in methods
26 (38)
Defined harms analysis population Based on actual treatment received (that is, including all patients who had received at least
one administration of treatment)
18
Intention to treat 5
All who started allocated treatment 2
All who completed allocated treatment 1
Harms analysis population not specifically
defined in methods
43 (62)
Inferred harms analysis population Stated ‘safety population’ without further definition 1
Apparently analysed as per efficacy outcomes 33
Intention to treat definition 31
Per protocol definition 2
No details given of harms or benefit analysis population 9
aThe number of trials with harms analyses presented (69) is used as the denominator for %.
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Human Use Good Clinical Practice (ICH GCP) E9 guide-
lines [16] state that ‘it may be reasonable to eliminate
from the set of all randomised subjects those who took
no trial medication. The ITT principle would be pre-
served despite the exclusion of these patients provided,
for example, that the decision of whether or not to
begin treatment could not be influenced by knowledge
of the assigned treatment.’ (Note that only one trial in
this review provided any justification for the exclusion
of such subjects.)
The 2001 CONSORT statement may inadvertently
have contributed to the incorrect use of the term "ITT
analysis" that was observed in our cohort of 2008 publi-
cations, and as such the phrase asking ‘whether the ana-
lysis was by “intention to treat”’ in the 2001 version of
CONSORT has been amended to ‘whether the analysis
was by original assigned groups’ in the 2010 version.
Harms analyses
A variety of analysis sets were used for the analysis of
harms data in this cohort of trials, and this may be a
consequence of the lack of consensus in the research lit-
erature on the appropriate harms analysis population to
be used in the event of departures from treatment proto-
col. The 2001 version of the CONSORT statement [12]
supports the view of Lewis and Machin [20] that ITT is
not appropriate for analysis of harms outcomes. Simi-
larly, the ICH GCP guidelines [16] suggest that analysis
of harms data should be according to treatment
received, that is, all participants who received at least
one dose of a treatment should be included in that treat-
ment group for harms analyses. This was the most com-
mon analysis set specifically defined for harms outcomes
in this review.However, the 2004 CONSORT extension for reporting
harms [44] conversely states that ITT is usually pre-
ferred for both benefit and harms outcomes because it
reflects the original trial design. The CONSORT 2010
statement has removed any reference to the appropriate-
ness or otherwise of ITT analysis populations for harms
outcomes.
The variation in the analysis populations chosen for
harms outcomes in the presence of treatment protocol
nonadherence suggests that explicit guidance is needed
on how harms data from patients who deviate from
treatment protocol should be analysed, for example,
what to do if a patient receives both or none of the trial
treatments, or if they receive a treatment to which they
were not randomised.
Importance of collecting adherence data in RCTs
Although ITT analysis is an important part of any trial,
there is a potential danger that the spirit of ITT could be
interpreted as an indication that collecting or reporting
data on the degree of adherence to the treatment proto-
col is unimportant. However, even when there is no
intention to formally investigate the relationship
between treatment uptake and outcome, reporting infor-
mation on the degree of intervention received is argu-
ably important to assess the degree to which the
intervention is even reaching the targeted population.
Otherwise it may not possible to judge whether an un-
favourable observed effect of treatment, for example,
may be in part due to non-receipt rather than ineffect-
iveness of the treatment, and if it is due to non-receipt
of the intervention, whether steps could be taken to im-
prove uptake of the treatment to potentially enhance
treatment effect. Indeed, an ITT analysis can only pro-
vide information on the effectiveness of the intervention
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policies on treatment changes) and according to the
level of adherence observed in the trial. In reality, the
implementation of the intervention in clinical practice
may differ, and adherence rates may improve (or dimin-
ish) directly because of dissemination of results from the
trial itself and resultant changes in expectation of the
intervention amongst users and clinicians. Thus, even
the interpretation of the effectiveness of an intervention
may be limited from an ITT analysis. Collecting infor-
mation on adherence and treatment changes that oc-
curred in the trial could potentially allow subsequent
statistical investigation into the impact of changes to ad-
ministration of the treatment or adherence rates on the
treatment effect [45]. Even in the case of so-called large,
simple trials, where emphasis lies on the collection of
limited data from a very large number of participants
[46], collection of adherence information from just a
small random subsample of patients may add to the clin-
ical interpretation of trial results without greatly increas-
ing the burden on participants or trial staff.
Another argument for reporting adherence informa-
tion in trial publications is the need to consider variation
in adherence rates across trials in a systematic review.
Such variation is a potential source of heterogeneity
even when true treatment effects are identical across
trials [19], as the choice of statistical analysis method in
the presence of departure from randomised treatment
can affect trial results and conclusions. The issue of
whether these differences in adherence rates should be
considered as a source of bias by statistical reviewers
depends on the purpose of the systematic review. If, as is
commonly the case, a systematic review aims to estimate
the effectiveness of a treatment in order to inform deci-
sions about health care policies, the issue of variable ad-
herence rates may not be considered a biasing factor.
Conversely, if the systematic review is focussing on an
estimation of treatment efficacy, it is unlikely that
reviewers will be able to appropriately allow for nonad-
herence without the availability of individual patient
data. However, given that choices made in the statistical
handling of nonadherence in trial publications can affect
trial outcomes and conclusions, it is important whatever
the research question for systematic reviewers to con-
sider whether differing degrees of adherence in trials
may be causing heterogeneity.
Increased interest in causal analysis
Ten trial reports in this review specifically discussed the
difficulty in interpreting trial results in the presence of
treatment protocol nonadherence (although only seven
of these trials actually carried out analyses that in some
way investigated the influence of the nonadherence to
treatment protocol). In addition, two cancer trialsdiscussed the related problem of how to interpret ITT
analysis in the face of substantial treatment changes that,
rather than being caused by nonadherence to treatment
protocol, are actually permitted by the protocol. In the
case of late stage cancer trials, it is common for treat-
ment protocols to allow patients to switch treatments or
receive additional salvage therapy at the point of disease
progression or relapse. This is a particular ethical re-
quirement in placebo-controlled trials, but is also be-
coming more common in trials comparing active
treatments, as a result of the increasing number of
second- and third-line therapies that are becoming avail-
able [47]. Although such trial designs do not impact on
the interpretation of the commonly used outcome
progression-free survival (defined as time to progression
or death), the analysis of overall survival is complicated
by the resultant merging of the treatment experience of
the randomised groups following progression, leading to
a diminished effect. Consideration of overall survival is
particularly important for patients and policy makers,
and thus interest is growing in how to address the issue
of treatment switches in order to provide unbiased and
clear treatment comparisons which are not available
from ITT, PP or AT analyses. Causal effect modelling
techniques are receiving attention as a potential solution
to the problem, and have recently been implemented to
guide decision makers [48-50].
Limitations
This review is limited by a sample size of 100 trial publi-
cations taken from only four high impact general med-
ical journals, and thus the generalisation of our results
to other less widely read or more subject-specific jour-
nals may be limited. However we would argue that, for
this reason, the findings evident from this review should
be regarded as an estimate of the upper limit of the
quality of reporting and analysis of nonadherence to
treatment protocol. As regards the critique of analysis
methods, because we did not contact trial authors dir-
ectly, we cannot be sure that the details reported in the
trial publications were complete and accurate accounts
of how analysis proceeded. As we did not have access to
the protocols or statistical analysis plans for the trials in
this review, it was not possible to ascertain whether the
analyses carried out to examine the effect of treatment
protocol deviations were decided prior to data collection
or were post hoc decisions. Two trials admitted that the
statistical method to deal with departures from treat-
ment protocol were post hoc analyses.
The main limitation of this review was the use of a
single reviewer for data extraction, although this re-
viewer was able to consult the opinion of a second re-
viewer whenever there was doubt as to appropriate
classifications. This was necessary, however, in less than
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from all trial reports was undertaken using clear defini-
tions for classification of results.
Conclusions
Nonadherence to treatment protocol is widespread among
trials and is recognised by some trialists as potentially ob-
scuring treatment efficacy, but statistical methods of ana-
lysis to handle such nonadherence typically exclude or
censor participants who deviate from the treatment proto-
col, without discussion of the potential bias introduced in
such an analysis. Nonadherence information presented in
trial reports can be ambiguous or scant, particularly relating
to treatment initiation and completeness. Reporting infor-
mation on the uptake and acceptance of treatment is im-
portant for the interpretation of the success of the trial
treatments, for clinicians, patients and health policy deci-
sion makers, even when the analysis does not aim to adjust
for nonadherence to treatment protocol. Trialists need to
be more aware of the importance of reporting the degree of
adherence to the treatment protocol.
Recommendations box for trialists
1. Trialists should document in the trial protocol how
they plan to measure and report nonadherence to
treatment protocol, with an explanation in protocol
and publication of why the chosen adherence
measure is clinically the most important and
relevant.
2. The decision on whether, and how, to examine the
effect of nonadherence to treatment protocol should
be made prior to data collection, and details of the
planned analyses should be documented in the
protocol (and statistical analysis plan) with an
explanation for proposed methods. Trial
publications should include a discussion of potential
bias introduced by any such analyses, and efforts
should be made in the statistical analysis to reduce
any bias introduced by excluding participants from
analysis.
3. Composition of analysis sets used for benefit and
harms outcomes should be defined explicitly, rather
than merely labelled as ITT or PP.
4. The total numbers of participants who were
randomised, excluded (with reasons) and analysed
for each outcome should be reported as
recommended in the CONSORT statement [13].
5. Potentially ambiguous phrases such as ‘protocol
deviations’, ‘completed study/treatment protocol’,
‘withdrawal’, ‘intention to treat’, ‘modified intention to
treat’, and ‘per protocol’ should be carefully defined
in terms of the treatment protocol if used in trial
reports.6. Trial reports should clearly distinguish between
withdrawal from treatment and withdrawal from
study: that is, they should clarify whether
participants withdrew from treatment but agreed to
continuing to provide follow-up data or whether
participants also withdrew from further follow-up,
and if the latter, whether or not they consented for
the data collected up to the point of withdrawal to
be included in the analysis.
7. Reporting of treatment receipt and completeness
should reflect the duration of trial intervention(s):
a. Trials with the intervention given at a single time
point should report the number of participants
who received the allocated intervention in each
randomised group.
b. Trials with a short-term intervention should
report the number of participants initiating and
completing allocated treatment as specified in the
protocol in each randomised group.
c. Trials with a long-term intervention should
report the number of participants initiating and
persisting with allocated treatment as specified in
the protocol, along with a measure of participant
and/or treatment provider adherence (as appropriate)
over the treatment period, in each randomised group.
8. Participant adherence should usually be assessed in
at least a random subsample of individuals in trials
involving participant-administered treatment using a
reliable method or, if necessary, using more than one
method to gauge the reliability of the assessment.
9. A biological or medical explanation should be
provided for any thresholds used to define adequate
adherence, and these should be specified in the trial
protocol.
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